Aurinia Pharmaceuticals (AUPH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Aurinia Pharmaceuticals is set to participate in the Jefferies London Healthcare Conference, engaging with investors through one-on-one meetings and a fireside chat. The company, known for its FDA-approved treatment for lupus nephritis, continues to advance its pipeline with promising therapies for autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
